Ophthalmic phototherapy system and associated method

• US 9,814,903 B2
• Filed: 04/25/2017
• Issued: 11/14/2017
• Est. Priority Date: 04/14/2005
• Status: Active Grant

• Current Assignee: Photospectra Health Sciences, Inc.
• Original Assignee: Photospectra Health Sciences, Inc.
• Inventors: Dotson, Robert S., Merry, Graham
• Primary Examiner(s): Downey, John R
• Application Number:
  US15/497,148
• Publication Number:
  US 20170225012A1
• Time in Patent Office: 203 Days
• CPC Class Codes: A61B 3/102 for optical coherence tomography [OCT]
• CPC Class Codes: A61B 3/12 for looking at the eye fundus, e.g. ophthalmoscopes A61B3/13 takes precedence
• CPC Class Codes: A61B 3/1241 specially adapted for observation of ocular blood flow, e.g. by fluorescein angiography
• CPC Class Codes: A61B 3/14 Arrangements specially adapted for eye photography apparatus or arrangements for taking photographs per se G03B
• CPC Class Codes: A61F 2009/00868 Ciliary muscles or trabecular meshwork
• CPC Class Codes: A61F 2009/00872 Cornea
• CPC Class Codes: A61F 2009/00891 Glaucoma
• CPC Class Codes: A61F 9/0079 using non-laser electromagnetic radiation, e.g. non-coherent light or microwaves
• CPC Class Codes: A61N 2005/0626 Monitoring, verifying, controlling systems and methods
• CPC Class Codes: A61N 2005/0644 Handheld applicators
• CPC Class Codes: A61N 2005/0652 Arrays of diodes
• CPC Class Codes: A61N 2005/0659 infrared
• CPC Class Codes: A61N 2005/0663 Coloured light
• CPC Class Codes: A61N 5/0613 Apparatus adapted for a specific treatment
• CPC Class Codes: A61N 5/067 using laser light

Abstract

An ophthalmic phototherapy device and associated phototherapy treatment method tor promoting healing of damaged or diseased eye tissue. The ophthalmic phototherapy device includes a light emitting mechanism for transmitting light of at least one preselected wavelength to the eye tissue. The ophthalmic phototherapy method includes directing light of at least one wavelength for a selected period of time to a portion of damaged or diseased eye tissue, whereby the light transmitted to the damaged or diseased eye tissue stimulates cellular activity in the eye tissue to promote healing.

Claims

1. A system for treating inflammatory eye disease inside an eye of a patient, comprising:

an ophthalmic imaging device; and

an ophthalmic phototherapy device that includes;

a first light-emitting mechanism comprising an LED or a low-power laser source, that in operation emits a first light of at least a first wavelength in a near infra-red light wavelength range, a yellow light wavelength range, or a red light wavelength range;

a second light-emitting mechanism comprising an LED or a low-power laser source, that in operation emits a second light of at least a second wavelength different from the first wavelength; and

a controller comprising processing circuitry that in operation controls the first and second light-emitting mechanism so as to selectively direct the first and the second light from the ophthalmic phototherapy device into the eye of the patient being treated by the ophthalmic phototherapy device for first and second preselected periods of time, respectively.

2. The system of claim 1, wherein the ophthalmic imaging device comprises an ocular coherence tomography (OCT) device.

3. The system of claim 1, wherein the ophthalmic imaging device comprises a fundus camera.

4. The system of claim 1, wherein the first wavelength is between approximately 490 nm and 810 nm.

5. The system of claim 1, wherein the second wavelength is in a near infra-red light wavelength range, a yellow light wavelength range, or a red light wavelength range, with the proviso that the first and second wavelengths are not both selected from the same wavelength range.

6. The ophthalmic phototherapy system of claim 1, wherein the processing circuitry when in operation:

(a) controls when or for how long each of the first light and the second light is emitted;

(b) enables emission of the first light and the second light at a preselected first brightness and a preselected second brightness, respectively;

(c) controls one of a combination, a pulsed combination, and a sequence in which the first light and the second light are emitted from the light-emitting mechanisms;

or

(d) performs any combination of (a)-(c).

7. The ophthalmic phototherapy system of claim 1, wherein each of the first light-emitting mechanism and the second light-emitting mechanism comprises an array of a plurality of LEDs, low power laser sources, or any combination thereof.

8. The ophthalmic phototherapy system of claim 7, wherein the processing circuitry when in operation:

(a) controls when or for how long each of the first light and the second light is emitted;

(b) enables emission of the first light and the second light at a preselected first brightness and a preselected second brightness, respectively;

(c) controls one of a combination, a pulsed combination, and a sequence in which the first light and second light are emitted from the light-emitting mechanisms;

(d) selectively controls the arrays of the first and second light-emitting mechanisms to vary the wavelength of light emitted from the light-emitting mechanisms;

or

(e) performs any combination of (a)-(d).

9. The ophthalmic phototherapy system of claim 1, wherein the ophthalmic phototherapy device further comprises a user interface configured to permit a user to select a treatment modality comprising delivering light of at least one of a sequence, combination or pulsed format of the first and second light into the eye of the patient.

10. The ophthalmic phototherapy system of claim 1, wherein at least a portion of the ophthalmic phototherapy device may be pivoted or rotated into position to emit the first light and the second light into the eye of the patient.

11. The ophthalmic phototherapy system of claim 1, wherein the ophthalmic phototherapy device further comprises a third light-emitting mechanism comprising an LED or a low power laser source, that in operation emits a third light of at least a third wavelength, wherein the third wavelength is different from the first and second wavelengths and wherein no two of the first wavelength, the second wavelength, and the third wavelength are both selected from a near infra-red light wavelength, a yellow-light wavelength, and a red-light wavelength.

12. The ophthalmic phototherapy system of claim 11, wherein each of the first, second, and third wavelengths is selected from a near infra-red light wavelength, a yellow-light wavelength, and a red-light wavelength.

13. The ophthalmic phototherapy system of claim 12, wherein one of the first, second, and third wavelengths is between approximately 577 nm and 597 nm, and wherein at least another of the first, second, and third wavelengths is between approximately 640 nm and 700 nm.

14. A method for treating inflammatory eye disease inside an eye of a patient, the method comprising:

receiving an ophthalmic image of the eye of the patient that indicates the presence of inflammatory disease in the eye;

providing an ophthalmic phototherapy device that includes (1) a first light-emitting device comprising an LED or a low power laser source, that in operation emits a first light of at least a first wavelength in a near infra-red light wavelength range, a yellow light wavelength range, or a red light wavelength range, (2) a second light-emitting device comprising an LED or a low power laser source, that in operation emits a second light of at least a second wavelength different from the first wavelength, and (3) a controller comprising processing circuitry that in operation controls the first and second light-emitting devices so as to selectively direct the first and second lights from the ophthalmic phototherapy device into the eye of the patient to be treated by the ophthalmic phototherapy device for first and second preselected periods of time, respectively;

directing, for the first preselected period of time, the first light into the eye of the patient to expose at least a portion of an affected eye tissue inside the eye to the first light, wherein the first light has a first preselected brightness; and

directing, for the second preselected period of time, the second light into the eye of the patient to expose the portion of the affected eye tissue to the second light, wherein the second light has a second preselected brightness,

wherein the first wavelength of the first light is different from the second wavelength of the second light.

15. The method according to claim 14, further comprising generating the ophthalmic image prior to the receiving the ophthalmic image.

16. The method according to claim 15, wherein generating the ophthalmic image comprises performing fluorescein angiography or ocular coherence tomography on the eye.

17. The method of claim 14, wherein the second wavelength is selected from a near infra-red light wavelength, a yellow light wavelength, and a red-light wavelength.

18. The method of claim 14, wherein the first wavelength is within the range of approximately 577 to 597 nm and the second wavelength is within the range of approximately 640 nm to 700 nm.

19. The method of claim 14, wherein the first light and the second light are directed into the eye of the patient in a manner comprising at least one of sequentially or in combination or in a pulsed format.

20. The method of claim 14 further comprising, during the treatment session, exposing the portion of the eye tissue to a third light of at least a third wavelength for a third preselected period of time, the third light having a third preselected brightness, wherein the third wavelength is different from the first and second wavelengths.

21. The method of claim 14, wherein the inflammatory eye disease comprises dry age-related macular degeneration.